| 摘要 |
Several embodiments disclosed herein relate to methods of providing an optimized drug therapy that is specialized or customized for an individual subject or a group of subjects based, at least in part, on one or more of the genetic profile of the subject, the pharmacogenomic profile of the subject, and/or evaluation of possible drug-drug interactions. In several embodiments, systems specialized for performing one or more aspects of the methods are provided. |
| 主权项 |
1. A method of developing a tailored drug therapy for a subject in need of the therapy, the method comprising:
receiving a genetic profile of the subject; obtaining a pharmacogenomics analysis of the subject, wherein said genetic profile of the subject is prepared by a method comprising:
processing a first set of data using a computer system configured to receive and assess the first set of data and provide an output comprising a second set of data,
said first set of data comprising information related to genetic sequences of biological materials obtained from diseased tissue of the subject, andsaid second set of data comprising information related to one or more genetic alternations or variants of the diseased tissue of the subject as compared to normal, non-diseased tissue, wherein said computer system comprises an algorithm that compares a data point from the first set of data with a corresponding data point from normal, non-diseased tissue; andwherein said computer system includes a communication interface that provides a two-way data communication coupling to a network link such that said first set of data is input using said communication interface, said first set of data communicates through said two-way data communication coupling with said second set of data, and said second set of data is output on said communication interface;processing the second set of data using said computer system, wherein said computer system is configured to receive and assess the second set of data and provide an output comprising a third set of data, said processing the second set of data comprising:
identifying differentially expressed genetic alterations or variants in the diseased tissue, andquerying an electronic drug database to identify a first set of candidate drugs that may be associated with an elevated degree of therapeutic efficacy against tissue exhibiting the one or more genetic alterations or variants identified in the diseased tissue of the subject, said third set of data comprising information related to the first set of candidate drugs; andwherein said second set of data is input using said communication interface, said second set of data communicates through said two-way data communication coupling with said third set of data, and said third set of data is output on said communication interface; wherein said pharmacogenomics analysis of the subject is generated by a method comprising:
processing a fourth set of data using said computer system, wherein said computer system is configured to receive and assess the fourth set of data, said fourth set of data comprising information related to the pharmacokinetic profile of the subject, wherein the pharmacokinetic profile of the subject was determined by screening the subject for characteristic identifiers of absorption, distribution, metabolism, and/or excretion of drugs, and wherein said fourth set of data is input using said communication interface;processing the third and fourth sets of data and a fifth set of data using a computer system, wherein said computer system is configured to receive and assess the third, fourth, and fifth sets of data, said fifth set of data comprising information related to a panel of drugs currently being administered or contemplated to be administered to the subject, said processing the third, fourth, and fifth sets of data comprising:
evaluating one or more of the following:
an impact of the pharmacokinetic profile of the subject on a recommended dosage amount of each of the first set of candidate drugs, andan impact of putative or actual drug-drug interactions for each of the first set of candidate drugs and one or more drugs currently being administered or contemplated to be administered to the subject; andproviding an output comprising a sixth set of data, said sixth set of data comprising information related to a second set of candidate drugs; andgenerating at least one report, wherein said report comprises a recommended panel of therapeutic drugs comprising the second set of candidate drugs and recommended dosing regimens for the panel, thereby developing a tailored drug therapy. |
